Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
wXELIRI vs FOLFIRI in advanced colorectal cancer
NCT01736904Phase 2Unknown
- Sponsor
- Fudan University
- Start
- May 2012
- Primary completion
- Dec 2014
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, capecitabine in colorectal cancer (CRC), sponsored by Fudan University. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01736904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01736904.